Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Chinese Herbal Acupoint Application Combined With Triple Antiemetic Therapy for Prevention of Chemotherapy-Induced Nausea and Vomiting in Breast Cancer

Efficacy and Safety of Chinese Herbal Acupoint Application Combined With Triple Antiemetic Therapy for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer: A Randomized Controlled Trial

The goal of this clinical trial is to learn whether Chinese herbal acupoint application, when added to standard three-drug anti-nausea treatment, can prevent nausea and vomiting caused by chemotherapy in people with breast cancer. The study will also evaluate the safety of the Chinese herbal acupoint application.

The main questions it aims to answer are:

  • Does Chinese herbal acupoint application help participants have less nausea during the first 5 days after chemotherapy?
  • Does it reduce vomiting and the need for additional anti-nausea medicine?
  • Does it affect the impact of chemotherapy-related nausea and vomiting on daily life?
  • What medical problems or side effects occur with the Chinese herbal acupoint application?

Researchers will compare Chinese herbal acupoint application with a sham application. Both groups will receive standard three-drug anti-nausea treatment. The sham application looks and feels similar to the herbal application but does not contain the active herbal ingredients.

Participants will:

  • Receive one cycle of planned chemotherapy and standard three-drug anti-nausea treatment.
  • Receive either the Chinese herbal acupoint application or sham application before chemotherapy. The application will be placed on selected acupuncture points for 4 to 6 hours.
  • Record nausea, vomiting, and use of additional anti-nausea medicine during the first 5 days after chemotherapy.
  • Complete a questionnaire about how nausea and vomiting affect daily life.
  • Have safety follow-up for about 2 weeks after chemotherapy.

Descripción general del estudio

Tipo de estudio

Intervencionista

Inscripción (Estimado)

190

Fase

  • Fase 2

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Ubicaciones de estudio

    • Zhejiang
      • Hangzhou, Zhejiang, Porcelana, 310009
        • Second Affiliated Hospital, School of Medicine, Zhejiang University
        • Contacto:

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Age ≥18 years, regardless of sex;
  • Pathologically confirmed operable breast cancer with no prior systemic chemotherapy;
  • Planned to receive one of the following highly emetogenic chemotherapy (HEC) regimens. HEC refers to chemotherapy regimens associated with an expected incidence of vomiting of >90% in the absence of prophylactic antiemetic treatment, including anthracycline/cyclophosphamide-based regimens (AC, TC, or EC) and carboplatin-containing regimens (e.g., TCbH, TCbHP);
  • Planned to receive triple antiemetic prophylaxis consisting of an NK-1 receptor antagonist, a 5-HT3 receptor antagonist, and dexamethasone. NK-1 receptor antagonists may include fosrolapitant, aprepitant, fosaprepitant, or other approved agents; 5-HT3 receptor antagonists may include palonosetron, ondansetron, or other approved agents;
  • Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0-1
  • Considered by the treating physician to be physically able to undergo and comply with the acupoint application procedure;
  • Adequate major organ function and bone marrow function。

Exclusion Criteria:

  • Skin damage, ulceration, scarring, or severe infection at the intended application sites;
  • Known history of severe allergy to any adhesive tape, patch materials, or herbal/other ingredients used in the study;
  • Significant nausea (VAS ≥25 mm) within 24 hours before chemotherapy that, in the investigator's judgment, is not related to chemotherapy;
  • Refractory vomiting due to non-chemotherapy-related causes, such as complete intestinal obstruction or severe vomiting caused by increased intracranial pressure secondary to brain metastases;
  • Pregnancy or breastfeeding;
  • Concomitant brain metastases, increased intracranial pressure, gastrointestinal obstruction, or other diseases that may cause nausea or vomiting;
  • Severe hepatic, renal, or cardiac dysfunction, or other serious underlying diseases that, in the investigator's judgment, make the participant unsuitable for the study;
  • Planned abdominal or pelvic radiotherapy within 7 days before randomization or during Days 1-7 of chemotherapy;
  • Use of antiemetic medications within 48 hours before chemotherapy, except for the routine prophylactic antiemetic regimen specified in the triple antiemetic therapy, or use of other medications that may affect the assessment of nausea or vomiting;
  • Severe psychiatric illness or cognitive impairment that prevents the participant from understanding the nausea/vomiting assessment scales or - complying with the 4-6-hour acupoint application procedure;
  • Inability to take oral medications;
  • Any other condition that, in the investigator's judgment, makes the participant unsuitable for participation in the study.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Único

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Chinese Herbal Acupoint Application

Participants will receive Chinese herbal acupoint application before chemotherapy on Day 1. The herbal paste contains Chinese herbal medicines and will be applied to the Conception Vessel 12 (CV12), Conception Vessel 8 (CV8), and bilateral Pericardium 6 (PC6) acupoints. The patch will remain in place for 4 to 6 hours and will then be removed. Participants will also receive standard three-drug antiemetic treatment as planned for their chemotherapy.

On Day 1, before chemotherapy, participants will receive Chinese herbal acupoint application in addition to standard triple antiemetic therapy. The herbal preparation consists of Ginger-processed Pinellia 90 g, Coptis Rhizome 30 g, Magnoliae Officinalis Cortex 120 g, Ginger-processed Caulis Bambusae in Taeniam 100 g, Evodia fruit 30 g, Dried Tangerine Peel 60 g, and clove flower bud 60 g. The herbs are mixed into powder. For each application, 50 g of herbal powder is mixed with 50 mL normal saline and 50 g medical petrolatum to form a paste. Approximately 1 cm-diameter herbal patches are prepared and applied to the Conception Vessel 12 (CV12), Conception Vessel 8 (CV8), and bilateral Pericardium 6 (PC6) acupoints. The patches are removed after 4-6 hours.

All participants will receive a standard triple antiemetic regimen consisting of an NK-1 receptor antagonist, a 5-HT3 receptor antagonist, and dexamethasone according to the study protocol and clinical practice. NK-1 receptor antagonists may include fosrolapitant, aprepitant, or fosaprepitant. 5-HT3 receptor antagonists may include palonosetron or ondansetron. The specific antiemetic agent and dosing regimen will be selected according to the chemotherapy regimen and the study protocol.

Comparador falso: Sham Acupoint Application

Participants will receive a sham acupoint application before chemotherapy on Day 1. The sham patch will have the same appearance, size, color, smell, and base material as the herbal patch, but will not contain any of the active Chinese herbal ingredients. The sham patch will remain in place for 4 to 6 hours and will then be removed. Participants will also receive standard three-drug antiemetic treatment as planned for their chemotherapy.

All participants will receive a standard triple antiemetic regimen consisting of an NK-1 receptor antagonist, a 5-HT3 receptor antagonist, and dexamethasone according to the study protocol and clinical practice. NK-1 receptor antagonists may include fosrolapitant, aprepitant, or fosaprepitant. 5-HT3 receptor antagonists may include palonosetron or ondansetron. The specific antiemetic agent and dosing regimen will be selected according to the chemotherapy regimen and the study protocol.

On Day 1, before chemotherapy, participants will receive sham acupoint application in addition to standard triple antiemetic therapy. The sham patches will be identical to the herbal patches in appearance, size, matrix color, odor, and backing material. The sham matrix will contain petrolatum, medical adhesive, and starch, without any active herbal ingredients. The sham patches are not intended to exert pharmacological effects through the skin. The patches will be applied to the Conception Vessel 12 (CV12), Conception Vessel 8 (CV8), and bilateral Pericardium 6 (PC6) acupoints and removed after 4-6 hours.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Proportion of Participants With No Significant Nausea (NSN) During 0-120 Hours After Chemotherapy
Periodo de tiempo: 0-120 hours after initiation of chemotherapy

No Significant Nausea (NSN) is defined as a nausea score consistently below 25 mm on a 100-mm visual analogue scale (VAS) throughout the 0-120-hour observation period after chemotherapy. The VAS ranges from 0 mm (no nausea) to 100 mm (worst imaginable nausea). The outcome measure is the proportion of participants who meet the criteria for NSN during the overall 0-120-hour observation period.

0-120 hours after initiation of chemotherapy

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Nausea Severity by VAS During Acute, Delayed, and Overall Periods
Periodo de tiempo: 0-120 hours after initiation of chemotherapy

Nausea severity will be assessed using a 100-mm visual analogue scale (VAS), with 0 mm indicating no nausea and 100 mm indicating the worst imaginable nausea. The maximum and mean VAS scores will be compared between the intervention and control groups during the acute period (0-24 hours), delayed period (24-120 hours), and overall period (0-120 hours) after chemotherapy.

0-120 hours after initiation of chemotherapy
Proportion of Participants With No Significant Nausea During Acute and Delayed Periods
Periodo de tiempo: 0-120 hours after initiation of chemotherapy

The proportion of participants with no significant nausea (NSN) will be compared between the intervention and control groups during the acute period (0-24 hours) and delayed period (24-120 hours) after chemotherapy. NSN is defined as a nausea VAS score consistently below 25 mm throughout the corresponding observation period.

0-120 hours after initiation of chemotherapy
Complete Response (CR) Rate During Acute, Delayed, and Overall Periods
Periodo de tiempo: 0-120 hours after initiation of chemotherapy

The proportion of participants achieving complete response (CR) will be compared between the intervention and control groups during the acute period (0-24 hours), delayed period (24-120 hours), and overall period (0-120 hours) after chemotherapy. CR is defined as no vomiting and no use of rescue antiemetic medication during the corresponding observation period.

0-120 hours after initiation of chemotherapy
Complete Control (CC) Rate During Acute, Delayed, and Overall Periods
Periodo de tiempo: 0-120 hours after initiation of chemotherapy

The proportion of participants achieving complete control (CC) will be compared between the intervention and control groups during the acute period (0-24 hours), delayed period (24-120 hours), and overall period (0-120 hours) after chemotherapy. CC is defined as no vomiting, no use of rescue antiemetic medication, and no significant nausea during the corresponding observation period. No significant nausea is defined as a nausea VAS score consistently below 25 mm throughout the corresponding observation period.

0-120 hours after initiation of chemotherapy
Proportion of Participants With No Impact of CINV on Daily Life
Periodo de tiempo: 120 hours after initiation of chemotherapy

The impact of chemotherapy-induced nausea and vomiting (CINV) on daily life will be assessed using the Functional Living Index-Emesis (FLIE). The proportion of participants with no impact of CINV on daily life will be compared between the intervention and control groups. A total FLIE score of ≥108 is defined as no impact on daily life.

120 hours after initiation of chemotherapy

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Investigador principal: Fuming Qiu, Second Affiliated Hospital, Zhejiang University, School of Medicine

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

1 de octubre de 2026

Finalización primaria (Estimado)

1 de agosto de 2028

Finalización del estudio (Estimado)

1 de agosto de 2028

Fechas de registro del estudio

Enviado por primera vez

24 de agosto de 2026

Primero enviado que cumplió con los criterios de control de calidad

27 de septiembre de 2026

Publicado por primera vez (Actual)

30 de septiembre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

30 de septiembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

27 de septiembre de 2026

Última verificación

1 de septiembre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir